-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Repligen (NASDAQ:RGEN) & ProKidney (NASDAQ:PROK) Financial Comparison
Repligen (NASDAQ:RGEN) & ProKidney (NASDAQ:PROK) Financial Comparison
ProKidney (NASDAQ:PROK – Get Rating) and Repligen (NASDAQ:RGEN – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.
Valuation & Earnings
This table compares ProKidney and Repligen's top-line revenue, earnings per share (EPS) and valuation.
Get ProKidney alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
ProKidney | N/A | N/A | -$2.33 million | N/A | N/A |
Repligen | $670.53 million | 15.43 | $128.29 million | $2.90 | 64.24 |
Repligen has higher revenue and earnings than ProKidney.
Analyst Ratings
This is a summary of current ratings for ProKidney and Repligen, as provided by MarketBeat.com.Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ProKidney | 0 | 1 | 5 | 0 | 2.83 |
Repligen | 0 | 2 | 5 | 0 | 2.71 |
ProKidney currently has a consensus price target of $15.20, indicating a potential upside of 60.51%. Repligen has a consensus price target of $224.14, indicating a potential upside of 20.31%. Given ProKidney's stronger consensus rating and higher probable upside, research analysts plainly believe ProKidney is more favorable than Repligen.
Institutional & Insider Ownership
91.0% of Repligen shares are owned by institutional investors. 1.1% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares ProKidney and Repligen's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
ProKidney | N/A | N/A | N/A |
Repligen | 20.76% | 10.98% | 8.14% |
Summary
Repligen beats ProKidney on 7 of the 9 factors compared between the two stocks.
About ProKidney
(Get Rating)
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
About Repligen
(Get Rating)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
ProKidney (NASDAQ:PROK – Get Rating) and Repligen (NASDAQ:RGEN – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.
普罗尼(纳斯达克:PROK-GET评级)和锐步(纳斯达克:rgen-GET评级)都是医疗公司,但哪一家是更优越的投资?我们将根据这两家公司的估值、收益、盈利能力、风险、机构所有权、分析师推荐和股息等方面的实力进行比较。
Valuation & Earnings
估值与收益
This table compares ProKidney and Repligen's top-line revenue, earnings per share (EPS) and valuation.
此表比较了ProKidney和Repligen的营收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
ProKidney | N/A | N/A | -$2.33 million | N/A | N/A |
Repligen | $670.53 million | 15.43 | $128.29 million | $2.90 | 64.24 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
原肾 | 不适用 | 不适用 | -233万元 | 不适用 | 不适用 |
复制 | 6.7053亿美元 | 15.43 | 1.2829亿美元 | $2.90 | 64.24 |
Repligen has higher revenue and earnings than ProKidney.
Repligen的收入和收益比ProKidney更高。
Analyst Ratings
分析师评级
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ProKidney | 0 | 1 | 5 | 0 | 2.83 |
Repligen | 0 | 2 | 5 | 0 | 2.71 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
原肾 | 0 | 1 | 5 | 0 | 2.83 |
复制 | 0 | 2 | 5 | 0 | 2.71 |
ProKidney currently has a consensus price target of $15.20, indicating a potential upside of 60.51%. Repligen has a consensus price target of $224.14, indicating a potential upside of 20.31%. Given ProKidney's stronger consensus rating and higher probable upside, research analysts plainly believe ProKidney is more favorable than Repligen.
ProKidney目前的共识目标价为15.20美元,表明潜在上行空间为60.51%。Repligen的一致目标价为224.14美元,表明潜在涨幅为20.31%。考虑到ProKidney更高的共识评级和更高的可能上行空间,研究分析师显然认为ProKidney比Repligen更有利。
Institutional & Insider Ownership
机构与内部人持股
91.0% of Repligen shares are owned by institutional investors. 1.1% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Repligen 91.0%的股份由机构投资者持有。Repligen 1.1%的股份由内部人士持有。强大的机构持股表明,捐赠基金、大型基金经理和对冲基金相信,从长期来看,一只股票的表现将好于大盘。
Profitability
盈利能力
This table compares ProKidney and Repligen's net margins, return on equity and return on assets.
此表比较了ProKidney和Repligen的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
ProKidney | N/A | N/A | N/A |
Repligen | 20.76% | 10.98% | 8.14% |
净利润率 | 股本回报率 | 资产回报率 | |
原肾 | 不适用 | 不适用 | 不适用 |
复制 | 20.76% | 10.98% | 8.14% |
Summary
摘要
Repligen beats ProKidney on 7 of the 9 factors compared between the two stocks.
Repligen在两只股票比较的9个因素中有7个击败了ProKidney。
About ProKidney
关于ProKidney
(Get Rating)
(获取评级)
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp.是一家临床阶段的生物技术公司,致力于开发细胞疗法候选药物。该公司正在开发肾脏自体细胞疗法,这是一种处于第三阶段开发计划的自体同源细胞混合物,以及治疗中到重度糖尿病肾脏疾病的第二阶段临床试验;以及针对肾脏和尿路先天性异常患者的第一阶段临床试验。该公司成立于2015年,总部位于北卡罗来纳州温斯顿-塞勒姆。
About Repligen
关于复制
(Get Rating)
(获取评级)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Repligen公司开发和商业化生物加工技术和系统,用于北美、欧洲、亚太地区和国际上的生物药物制造工艺。它提供蛋白A配体,即蛋白A亲和层析树脂的结合成分;以及细胞培养生长因子产品。该公司的层析产品包括用于生物制剂纯化的OPUS预填充色谱柱,以及用于高通量过程开发筛选、病毒清除验证研究和层析过程的缩小验证的OPUS小型色谱柱。它还提供ELISA检测试剂盒;以及Captiva品牌的层析树脂。此外,该公司还提供过滤产品,如用于上游灌流和细胞培养处理的过滤设备Xcell交替切向流系统;用于下游生物药物浓缩和配方工艺的TangenX平板滤筒;KrosFlo切向流过滤和切向流深度过滤系统;Spectra/Por实验室和过程透析产品、spectraFlo动态透析系统;以及ProConneX一次性使用的中空纤维。此外,它还提供过程分析产品,例如SoloVPE、FlowVPE和FlowVPX品牌的斜率光谱分析系统。该公司将其产品销售给生命科学、生物制药和诊断公司、实验室研究人员和合同制造组织。Repligen公司与Navigo Proteins GmbH签署了合作协议,以开发多种亲和配体。Repligen公司成立于1981年,总部设在马萨诸塞州沃尔瑟姆。
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
接受ProKidney Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ProKidney和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧